ArticleNature metabolism2026
A non-classical biosynthetic route enables tocopherol synthesis in bacteria.
Article in Nature metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbial catalysts unlock vitamin bioproduction.Nature metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Tocopherols have been widely applied in healthcare, medicine, animal feed and other fields. However, microbial synthesis of tocopherols with industrial potential has not been accomplished yet. Here we report a non-classical biosynthetic route for tocopherol synthesis in Rhodobacter species that bypasses the classical α-tocopherol pathway requiring the 2,3-dimethyl-5-phytyl-1,4-benzoquinone (DMPBQ) as an intermediate. In particular, a Rhodobacter methyltransferase with bifunctional γ/β-tocopherol methyltransferase activities is identified, which can directly synthesize α-tocopherol from δ-tocopherol and γ/β-tocopherols. Furthermore, geranylgeranyl pyrophosphate reductase (GR) plays an important role in reducing tocotrienols into tocopherols. Through systematic metabolic engineering, the engineered Rhodobacter sphaeroides produced a total titer of 508.21 mg l
Indexed as
Identifiers
42509462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.